TABLE 1.
MICs of consecutive C. glabrata isolates
| Drug | MIC (μg/ml) for isolate (day/mo/yr isolated)a |
||||
|---|---|---|---|---|---|
| 1 (08.12.2001) | 2 (03.01.2002) | 3 (07.01.2002) | 4 (14.03.2002) | 5 (16.03.2002) | |
| Amphotericin B | 1 | 2 | 0.75 | 0.75 | 0.75 |
| Flucytosine | 0.004 | >32 | >32 | 0.004 | 0.004 |
| Fluconazole | 8 | 2 | 1 | >256 | >256 |
| Voriconazole | 0.25 | 0.125 | 0.047 | 12 | 16 |
| Caspofungin | 0.19 | 0.125 | 0.125 | >32 | >32 |
a
Susceptibility testing was performed using the Etest method (AB-Biodisk, Sweden) according to the manufacturer's instructions. C. parapsilosis ATCC 22019 served as the control strain. MIC interpretative criteria for the susceptibility to FLC, VRC, and 5FC were as previously published by the CLSI (14, 17). The susceptibility breakpoint of ≤2 mg/liter was applied for CSF (15).